Overview of the drug development for keratitis
Keratitis is an inflammatory disease, which is caused by an infection that affects the cornea of an eye. Keratitis is sometimes caused by a bacterial, viral, or fungal infection. Bacterial keratitis mainly affects contact lens wearers. Poor contact lens hygiene, the use of multipurpose contact lens solutions, and the overnight use of contact lenses can lead to keratitis. People with HSV-1 can also develop herpes keratitis, a viral infection. If HSV-1 is present in the body, it can typically infect the eyelid, cornea, and conjunctiva. It keratitis is left untreated, it can also lead to vision loss. According to the 2014 CDC’s report, around 1 million people visit eye clinics annually for the treatment of keratitis in the US. Acanthamoeba keratitis primarily affects those who wear contact lenses. According to CDC, in 2017, around 85% of the total keratitis patients were contact lens wearers. With the rising incidences of the disease, the need for drug development for keratitis is expected to rise considerably in the forthcoming years.
According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for neurotrophic keratitis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of keratitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Adamis Pharmaceuticals
- Editas Medicine
- EyeGate
- INNOVATION
- iVeena Delivery Systems
Therapeutic assessment of the drug development for keratitis by route of administration
- Ophthalmic
- Oral
- Topical
The ophthalmic route of administration (ROA) involves the application of the drug and administered as a cream, an ointment, or a liquid drop, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development for keratitis by therapy
- Monotherapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development for keratitis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for keratitis?
- What are the companies that are currently involved in the development of drug molecules for keratitis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.